ConductScience.org, home

Paper20021206

Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development.

Chemin I. Future Oncol, 2010. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development. Papers, record 20021206. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20021206

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development.
PubMed
Journal
Future Oncol
PubMed
Year
2010
PubMed
Publication types
Comment, Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.18
iCite
Revised in PubMed
2009-12-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chemin IIsabelle

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment on19759364Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.https://conductscience.org/library/papers/19759364

Source PubMed

Download CSV of comments and corrections

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
35632549The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma.Vaccines (Basel)2022https://conductscience.org/library/papers/35632549PubMed
33092083A Methylation-Based Reclassification of Bladder Cancer Based on Immune Cell Genes.Cancers (Basel)2020https://conductscience.org/library/papers/33092083PubMed
32392361Classification of diffuse lower-grade glioma based on immunological profiling.Mol Oncol2020https://conductscience.org/library/papers/32392361PubMed
31936595Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines.Cancers (Basel)2020https://conductscience.org/library/papers/31936595PubMed
31575023Current Perspectives in Cancer Immunotherapy.Cancers (Basel)2019https://conductscience.org/library/papers/31575023PubMed
27107038Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.Cancer Discov2016https://conductscience.org/library/papers/27107038PubMed
23864445Both HCV and HBV are major causes of liver cancer in Southeast Asians.J Immigr Minor Health2013https://conductscience.org/library/papers/23864445PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20021206

GET https://conductscience.org/api/papers/v1/20021206/authors